The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. During the last U10 grant cycle we increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, commensurate with available SWOG funding and added resources from USC. The major emphases of the USC team are (a) to explore the utility of molecular prognostication with the correlation of specific genes with outcomes of therapy;(b) to investigate novel strategies of chemotherapy for common solid tumors in cancer patients, with a particular emphasis on minority populations and the elderly;(c) to develop novel strategies of prevention of GU and Gl cancers. Thus, USC investigators have contributed extensively to SWOG trials and administrative/academic leadership, facilitating the translation of specific themes of investigation to SWOG. Activities have included (a) administrative and scientific leadership (Vice Chairs of GU Committee and Gl Committee;cadre membership in Breast, Melanoma and Committee for Women/Special Populations;Scientific Advisory Board;External Advisory Boards of EORTC and Cancer Research UK;Data and Safety Monitoring Committee of SWOG;core labs for pharmacology and molecular prognostication studies of GU and Gl Committees);(b) mentoring through the Young Investigator Program with 2 Young Investigator Awards;(c) scientific research agendas translated from USC to SWOG including circulating tumor cells in SWOG prostate clinical trials, a NCI funded R01 to identify molecular markers for patients enrolled in SWOG 9304 and developed two prospecitve clinical trials to establish molecular markers in gastric and colon cancer (d) continuing high levels of clinical trial accrual with majority of cases from USC (e) development of a Minority Recruitment Strategies which is integrated into the overall strategy of the Norris Comprehensive Cancer Center, has resulted in the provision of a broad range of clinical and translational trials for minority populations leading to a continued improvement in access to clinical trials, particularly for Latino population groups (f) Increase the leadership of USC to improve cancer chemotherapy among the elderly, another under-served population group.
Through funding the USC/Norris Comprehensive Cancer Center will be able to provide significant translational research data and projects which will impact the design and development of clinical trials within SWOG. This grant will allow to continue our efforts in improving cancer chemotherapy to minority and ederly population we serve in Los Angeles County.
|Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Ulrich, Cornelia M; Rankin, Cathryn; Toriola, Adetunji T et al. (2014) Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304). Cancer 120:3329-37|
|Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32|
|Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5|
|Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48|
|Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
Showing the most recent 10 out of 115 publications